Clinical Study of Pulp Mesenchymal Stem Cells in the Treatment of Primary Mild to Moderate Knee Osteoarthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-04-04

Study Completion Date

2021-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the clinical efficacy and safety of dental pulp mesenchymal stem cells in the treatment of primary mild to moderate knee osteoarthritis through a comparative study with sodium hyaluronate.

20 participants will receive low dose of dental pulp mesenchymal stem cells, 20 participants will receive high dose and another 20 participants will receive sodium hyaluronate

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Autologous Adipose Tissue Derived Mesenchymal Stem Cells Therapy for Patients With Knee Osteoarthritis

NCT01809769

Knee Osteoarthritis

COMPLETED PHASE1/PHASE2

Mesenchymal Stem Cell Treatment for Primary Osteoarthritis Knee

NCT02544802

Osteoarthritis Knee

COMPLETED PHASE1

Intra-articular Injection of MSCs in Treatment of Knee OA

NCT03028428

Osteoarthritis Stem Cells MSC

UNKNOWN PHASE2

Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis

NCT06570291

Knee Osteoarthritis

RECRUITING PHASE3

Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis

NCT02641860

Osteoarthritis

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

60 participants will receive to evaluate the clinical efficacy and safety of dental pulp mesenchymal stem cells in the treatment of primary mild to moderate knee osteoarthritis through a comparative study with sodium hyaluronate and verify the basis of dental pulp mesenchymal stem cells in the treatment of primary knee osteoarthritis, and to explore a more effective and safe clinical treatment of knee osteoarthritis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Knee Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

low dose of dental pulp mesenchymal stem cells high dose of dental pulp mesenchymal stem cells Sodium hyaluronate

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low Dose of Mesenchymal stem cell

Patients receiving intraarticular injection of low dose of mesenchymal stem cells.

Group Type EXPERIMENTAL

Low Dose of Mesenchymal stem cell

Intervention Type BIOLOGICAL

Mesenchymal stem cell injection

High Dose of Mesenchymal stem cell

Patients receiving intraarticular injection of high dose of mesenchymal stem cells.

Group Type EXPERIMENTAL

High Dose of Mesenchymal stem cell

Intervention Type BIOLOGICAL

Mesenchymal stem cell injection

Sodium Hyaluronate

Patients receiving intraarticular injection of Sodium Hyaluronate

Group Type ACTIVE_COMPARATOR

Sodium Hyaluronate

Intervention Type DRUG

Sodium Hyaluronate injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Low Dose of Mesenchymal stem cell

Mesenchymal stem cell injection

Intervention Type BIOLOGICAL

High Dose of Mesenchymal stem cell

Mesenchymal stem cell injection

Intervention Type BIOLOGICAL

Sodium Hyaluronate

Sodium Hyaluronate injection

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

1 2 3

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Complying with the diagnostic criteria for primary knee osteoarthritis revised by the American Rheumatological Association (1995), age 40-70 years, gender-free.
2. For patients with mild to moderate knee arthritis, the WOMAC score of knee joint was less than 120.
3. X-ray Kellgren-Lawrence was used to evaluate the grade I, II and III of osteoarthritis.
4. Fertility patients should take effective contraceptive measures until the end of follow-up. Fertility women should exclude the possibility of early pregnancy, that is, HCG negative test in early pregnancy.
5. Voluntary participation in this clinical study, can cooperate with doctors to carry out research, stop all medical measures for knee arthritis for more than 2 weeks, and sign the informed consent of patients.

Exclusion Criteria

(1) Those with other diseases that may affect the knee joint, such as rheumatoid arthritis, ankylosing spondylitis, rheumatoid arthritis, gout and other rheumatic diseases, bone tumors, osteoporosis, bone tuberculosis or obvious history of acute trauma, resulting in meniscus injury, ligament rupture and vascular nerve injury; those with previous history of femur, tibial plateau, tibia and fibula fracture. The patients with gonarthritis, the patients with knee joint and surrounding skin infection were not cured.

2\) Patients who have undergone surgery and other factors affecting the efficacy of the treatment. Patients with severe deformities or even deformities of the knee joint, who need surgical treatment. Patients who have received knee joint irrigation or arthroscopic examination within one year.

3\) Patients with systemic cancer tendency or cancer and patients with systemic infection in active stage.

4\) Patients with severe heart, lung, liver, kidney, blood system, endocrine system and immune deficiency, or abnormal laboratory biochemical indicators, namely: hemoglobin (Hb) \< 9 g/dL, white blood cell (WBC) \> 15 x 109/L, platelet (Pt) \< 100 x 109/L, glutamic oxalate transaminase (AST) and alanine aminotransferase (ALT) \> 1.5 times normal upper limit; serum creatinine \> 1.5 times normal upper limit.

5\) Physical history or clinical manifestations with bleeding tendency, including patients currently using anticoagulants.

6\) Patients with uncontrollable epileptic seizures, psychosis or Alzheimer's disease who are unable to complete the scale.

7\) Pregnant or lactating women, legal disabled patients (blind, deaf, dumb, mentally retarded, physically disabled), drug addiction and other adverse drug addiction.

8\) Patients with contraindications or allergies were examined and treated in this study.

9\) Those who have participated in other clinical studies within one month.

10\) Researchers consider it inappropriate for patients to participate in this clinical study.

Minimum Eligible Age

40 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No